biostudies-literatureKroon JNanoNextNL Drug Delivery programme 03D.01the Netherlands OrganisationEuropean Research CouncilDutch Cancer SocietyPRONET815-24https://www.ebi.ac.uk/biostudies/studies/S-EPMC5006873biostudies-literatureUnknown75(8)<h4>Background</h4>The inflammatory tumor microenvironment, and more specifically the tumor-associated macrophages, plays an essential role in the development and progression of prostate cancer towards metastatic bone disease. Tumors are often characterized by a leaky vasculature, which - combined with the prolonged circulation kinetics of liposomes - leads to efficient tumor localization of these drug carriers, via the so-called enhanced permeability and retention (EPR) -effect. In this study, we evaluated the utility of targeted, liposomal drug delivery of the glucocorticoid dexamethasone in a model of prostate cancer bone metastases.<h4>Methods</h4>Tumor-bearing Balb-c nu/nu mice were treated intravenously with 0.2-1.0-5.0 mg/kg/week free- and liposomal DEX for 3-4 weeks and tumor growtThe ProstateLiposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.PMC5006873UL-2011-4030309494916.131.10309494:NeoNaNovan Bloois LCheung Hvan der Horst GBuijs JTPelger RCStorm GMetselaar JMLammers Tvan der Pluijm Gvan der Mark MKroon JRizzo LYfalseLiposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.<h4>Background</h4>The inflammatory tumor microenvironment, and more specifically the tumor-associated macrophages, plays an essential role in the development and progression of prostate cancer towards metastatic bone disease. Tumors are often characterized by a leaky vasculature, which - combined with the prolonged circulation kinetics of liposomes - leads to efficient tumor localization of these drug carriers, via the so-called enhanced permeability and retention (EPR) -effect. In this study, we evaluated the utility of targeted, liposomal drug delivery of the glucocorticoid dexamethasone in a model of prostate cancer bone metastases.<h4>Methods</h4>Tumor-bearing Balb-c nu/nu mice were treated intravenously with 0.2-1.0-5.0 mg/kg/week free- and liposomal DEX for 3-4 weeks and tumor growt2015-01-01T00:00:00Z2015 Jun2026-03-16T15:57:56.242Z2025-08-28T03:08:55.153ZS-EPMC50068732566307610.1002/pros.22963